[Federal Register Volume 62, Number 14 (Wednesday, January 22, 1997)]
[Notices]
[Pages 3298-3299]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-1532]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development.

ADDRESSES: Licensing information and a copy of the U.S. patent 
application referenced below may be obtained by contacting George H. 
Keller, Ph.D., at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804 (telephone 301/496-7735 ext. 246; fax 301/402-
0220). A signed Confidential Disclosure Agreement will be required to 
receive a copy of the patent application.

Hepatitis A Virus Receptor and Methods of Use

G Kaplan, SM Feinstone (FDA)

Serial No. 08/287,001 filed 05 Aug 94

    This invention describes the discovery and isolation of HAVcr-1, a 
simian cellular receptor for the hepatitis A virus (HAV). Cells 
nonpermissive to HAV infection transfected with HAVcr-1 cDNA, a novel 
cell surface mucin-like glycoprotein, gain susceptibility to HAV 
infection. The invention claims nucleic acids encoding cellular 
receptors to HAV which hybridize with HAVcr-1 probes. The invention 
also claims peptides encoded by the above-mentioned HAV receptor 
nucleic acid.
    Potential areas of application include use of HAVcr-1 receptors for 
diagnostics; use of HAVcr-1 receptors for treatment of patients 
infected with HAV; development of compounds capable of interacting with 
HAVcr-1 receptors which could inhibit HAV

[[Page 3299]]

infection and be used to treat HAV infected patients; development of 
transgenic animals for HAV vaccine production and testing.
    HAVcr-1 has recently been molecularly cloned and its cDNA is 
available for further development. A Notice of Allowance has recently 
been issued on this case by the U.S. Patent and Trademark Office; 
foreign rights are also available. This invention is available for 
licensing on an exclusive or nonexclusive basis.

    Dated: January 9, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-1532 Filed 1-21-97; 8:45 am]
BILLING CODE 4140-01-M